Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-038860
Filing Date
2025-08-07
Accepted
2025-08-07 16:05:16
Documents
62
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q sgmo-20250630.htm   iXBRL 10-Q 1021267
2 EX-31.1 sgmo-20250630xex311.htm EX-31.1 9870
3 EX-31.2 sgmo-20250630xex312.htm EX-31.2 9985
4 EX-32.1 sgmo-20250630xex321.htm EX-32.1 7046
  Complete submission text file 0001628280-25-038860.txt   5573052

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT sgmo-20250630.xsd EX-101.SCH 42915
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT sgmo-20250630_cal.xml EX-101.CAL 54899
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT sgmo-20250630_def.xml EX-101.DEF 191943
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT sgmo-20250630_lab.xml EX-101.LAB 524928
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT sgmo-20250630_pre.xml EX-101.PRE 372634
65 EXTRACTED XBRL INSTANCE DOCUMENT sgmo-20250630_htm.xml XML 656033
Mailing Address 501 CANAL BLVD. RICHMOND CA 94084
Business Address 501 CANAL BLVD. RICHMOND CA 94084 5109706000
SANGAMO THERAPEUTICS, INC (Filer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-30171 | Film No.: 251193875
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)